Dmitry L. Vinogradov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Dmitry L. Vinogradov has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
V. V. Vasilenko
3 shared publications- Vladislav Deigin
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Miklukho-Maklaya st., 16/10, 117997 Moscow, Russia
3 shared publications - Yulia E. Vinogradova
The Department of Hospital Therapy No. 2, I.M. Sechenov First Moscow State Medical University, 8 Trubetskaya Str., 119048 Moscow, Russia
3 shared publications - Alexander Krasichkov
Department of Radio Engineering Systems of Electrotechnical University LETI, 5F Prof. Popova Str., 197022 St. Petersburg, Russia
2 shared publications Array С. Бурлакова
Первый Московский государственный медицинский университет имени И. М. Сеченова
2 shared publications- Dmitrii Stanislavovich Medvedev
Saint-Petersburg Medico-Social Institute; Saint-Petersburg Institute of Bioregulation and Gerontology
2 shared publications
Latest Publications
- Open Access
- 13 December 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (24) , 13385
Novel Peptidomimetic Cyclo-{E(I)-E(W)}Na (CP-88) with Hematopoietic Activity Sustained in Invasive and Oral Administration: Experimental and Preclinical Evaluation
Over the last decades, significant progress has been made in studying agonistic and antagonistic hematopoietic peptides. The main disadvantage of this class of peptides is their low stability with noninvasive administration methods, which limits the widespread use of hematopoiesis-regulated peptide drugs in medical practice. The aim of this work is to study novel peptidomimetics with hematopoietic activity sustained in invasive and oral administration. The activity of the leading compound cyclopeptide Cyclo—[Glu(Ile)-Glu(Trp)] (CP-88) was compared to that of the pharmaceutical preparation Stemokin in stimulating the population of committed colony-forming cells in intact and irradiated mice. CP-88 peptide increases the relative number of CD34+ cells in the blood and bone marrow, leading to expanded hematopoietic stem cells. CP-88 peptide, applied 48 h before bone marrow extraction, stimulates the population of committed colony-forming cells in the normal bone marrow by 33–37% above the normal level. In recipient mice injected with irradiated bone marrow, this peptide was restored practically to normal levels of colony-forming cells in a wide range of doses at intraperitoneal and oral administration. The toxicological results conclude that in humans, considering interspecies extrapolation, the CP-88 peptide can be practically safe with a single and course administration in doses of up to 100 μg/kg. The results of this investigation underscore the significant potential of CP-88 peptide as a hematopoiesis-regulated drug and instill optimism for its future application in medical practice.
- 13 December 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (24) , 13385
Open AccessNovel Peptidomimetic Cyclo-{E(I)-E(W)}Na (CP-88) with Hematopoietic Activity Sustained in Invasive and Oral Administration: Experimental and Preclinical Evaluation
Over the last decades, significant progress has been made in studying agonistic and antagonistic hematopoietic peptides. The main disadvantage of this class of peptides is their low stability with noninvasive administration methods, which limits the widespread use of hematopoiesis-regulated peptide drugs in medical practice. The aim of this work is to study novel peptidomimetics with hematopoietic activity sustained in invasive and oral administration. The activity of the leading compound cyclopeptide Cyclo—[Glu(Ile)-Glu(Trp)] (CP-88) was compared to that of the pharmaceutical preparation Stemokin in stimulating the population of committed colony-forming cells in intact and irradiated mice. CP-88 peptide increases the relative number of CD34+ cells in the blood and bone marrow, leading to expanded hematopoietic stem cells. CP-88 peptide, applied 48 h before bone marrow extraction, stimulates the population of committed colony-forming cells in the normal bone marrow by 33–37% above the normal level. In recipient mice injected with irradiated bone marrow, this peptide was restored practically to normal levels of colony-forming cells in a wide range of doses at intraperitoneal and oral administration. The toxicological results conclude that in humans, considering interspecies extrapolation, the CP-88 peptide can be practically safe with a single and course administration in doses of up to 100 μg/kg. The results of this investigation underscore the significant potential of CP-88 peptide as a hematopoiesis-regulated drug and instill optimism for its future application in medical practice.
- Open Access
- 6 May 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (9) , 5042
The First Reciprocal Activities of Chiral Peptide Pharmaceuticals: Thymogen and Thymodepressin, as Examples
Peptides show high promise in the targeting and intracellular delivery of next-generation biotherapeutics. The main limitation is peptides’ susceptibility to proteolysis in biological systems. Numerous strategies have been developed to overcome this challenge by chemically enhancing the resistance to proteolysis. In nature, amino acids, except glycine, are found in L- and D-enantiomers. The change from one form to the other will change the primary structure of polypeptides and proteins and may affect their function and biological activity. Given the inherent chiral nature of biological systems and their high enantiomeric selectivity, there is rising interest in manipulating the chirality of polypeptides to enhance their biomolecular interactions. In this review, we discuss the first examples of up-and-down homeostasis regulation by two enantiomeric drugs: immunostimulant Thymogen (L-Glu-L-Trp) and immunosuppressor Thymodepressin (D-Glu(D-Trp)). This study shows the perspective of exploring chirality to remove the chiral wall between L- and D-biomolecules. The selected clinical result will be discussed.
- 6 May 2024
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 25 (9) , 5042
Open AccessThe First Reciprocal Activities of Chiral Peptide Pharmaceuticals: Thymogen and Thymodepressin, as Examples
Peptides show high promise in the targeting and intracellular delivery of next-generation biotherapeutics. The main limitation is peptides’ susceptibility to proteolysis in biological systems. Numerous strategies have been developed to overcome this challenge by chemically enhancing the resistance to proteolysis. In nature, amino acids, except glycine, are found in L- and D-enantiomers. The change from one form to the other will change the primary structure of polypeptides and proteins and may affect their function and biological activity. Given the inherent chiral nature of biological systems and their high enantiomeric selectivity, there is rising interest in manipulating the chirality of polypeptides to enhance their biomolecular interactions. In this review, we discuss the first examples of up-and-down homeostasis regulation by two enantiomeric drugs: immunostimulant Thymogen (L-Glu-L-Trp) and immunosuppressor Thymodepressin (D-Glu(D-Trp)). This study shows the perspective of exploring chirality to remove the chiral wall between L- and D-biomolecules. The selected clinical result will be discussed.
- Open Access
Role of Genetic Thrombophilia Markers in Thrombosis Events in Elderly Patients with COVID-19
Thrombosis is an extremely dangerous complication in elderly patients with COVID-19. Since the first months of the pandemic, anticoagulants have been mandatory in treatment protocols for patients with COVID-19, unless there are serious contraindications. We set out to discover if genetic thrombophilia factors continue to play a triggering role in the occurrence of thrombosis in patients with COVID-19 with prophylactic or therapeutic anticoagulants. We considered the following genetic markers as risk factors for thrombophilia: G1691A in the FV gene, C677T and A1298C in the MTHFR gene, G20210A and C494T in the FII gene, and (−675) 4G/5G in the PAI-I gene. In a cohort of 176 patients, we did not obtain a reliable result indicating a higher risk of thrombotic complications when taking therapeutic doses of anticoagulants in carriers of genetic markers for thrombophilia except the C494T mutation in the FII gene. However, there was still a pronounced tendency to a higher incidence of thrombosis in patients with markers of hereditary thrombophilia, such as FV G1691A and FII G20210A mutations. The presence of the C494T (Thr165Met) allele in the FII gene in this group of patients showed a statistically significant effect of the mutation on the risk of thrombotic complications despite anticoagulant therapy.
Open AccessRole of Genetic Thrombophilia Markers in Thrombosis Events in Elderly Patients with COVID-19
Thrombosis is an extremely dangerous complication in elderly patients with COVID-19. Since the first months of the pandemic, anticoagulants have been mandatory in treatment protocols for patients with COVID-19, unless there are serious contraindications. We set out to discover if genetic thrombophilia factors continue to play a triggering role in the occurrence of thrombosis in patients with COVID-19 with prophylactic or therapeutic anticoagulants. We considered the following genetic markers as risk factors for thrombophilia: G1691A in the FV gene, C677T and A1298C in the MTHFR gene, G20210A and C494T in the FII gene, and (−675) 4G/5G in the PAI-I gene. In a cohort of 176 patients, we did not obtain a reliable result indicating a higher risk of thrombotic complications when taking therapeutic doses of anticoagulants in carriers of genetic markers for thrombophilia except the C494T mutation in the FII gene. However, there was still a pronounced tendency to a higher incidence of thrombosis in patients with markers of hereditary thrombophilia, such as FV G1691A and FII G20210A mutations. The presence of the C494T (Thr165Met) allele in the FII gene in this group of patients showed a statistically significant effect of the mutation on the risk of thrombotic complications despite anticoagulant therapy.
- Open Access
Thymodepressin—Unforeseen Immunosuppressor
The paper summarizes the available information concerning the biological properties and biomedical applications of Thymodepressin. This synthetic peptide drug displays pronounced immunoinhibitory activity across a wide range of conditions in vitro and in vivo. The history of its unforeseen discovery is briefly reviewed, and the current as well as potential expansion areas of medicinal practice are outlined. Additional experimental evidence is obtained, demonstrating several potential advantages of Thymodepressin over another actively used immunosuppressor drug, cyclosporin A.
Open AccessThymodepressin—Unforeseen Immunosuppressor
The paper summarizes the available information concerning the biological properties and biomedical applications of Thymodepressin. This synthetic peptide drug displays pronounced immunoinhibitory activity across a wide range of conditions in vitro and in vivo. The history of its unforeseen discovery is briefly reviewed, and the current as well as potential expansion areas of medicinal practice are outlined. Additional experimental evidence is obtained, demonstrating several potential advantages of Thymodepressin over another actively used immunosuppressor drug, cyclosporin A.
- Open Access
- 1 January 2017
- Published by Synapse, LLC in The Russian Archives of Internal Medicine
- Vol. 7 (2) , 95-106
IGG4-RELATED DISEASE: CONDITION OF THE PROBLEM
Физиологическая роль IgG4 еще не до конца изучена. Известно, что они, как и другие антитела, участвуют в инактивации и удалении из организма веществ, идентифицированных иммунной системой, как чужеродные антигены. Также IgG4 реализуют эффекторные механизмы: связывание со специализированными иммунными клетками, осуществляющими после такого взаимодействия фагоцитоз чужеродных агентов или уничтожение зараженных клеток организма за счет зависимой от антител цитотоксичности. Мнения относительно способности IgG4 активировать комплемент зачастую противоречивы. Повышение концентрации иммуноглобулинов данного подкласса может свидетельствовать не только о развитии инфекционных и аллергических состояний, но и о наличии у пациента IgG4-сопряженной патологии. IgG4-сопряженная патология (IgG4-СП) — относительно недавно выделенная группа патологических состояний, и ее изучение становится все более актуальным. Это связано с тем, что она включает в себя состояния, которые ранее считались самостоятельными нозологическими единицами. В последние годы IgG4-СП диагностируется все чаще, так как получает все большее признание у медицинской общественности. Данный обзор включает новейшую информацию из последних зарубежных публикаций.
- 1 January 2017
- Published by Synapse, LLC in The Russian Archives of Internal Medicine
- Vol. 7 (2) , 95-106
Open AccessIGG4-RELATED DISEASE: CONDITION OF THE PROBLEM
Физиологическая роль IgG4 еще не до конца изучена. Известно, что они, как и другие антитела, участвуют в инактивации и удалении из организма веществ, идентифицированных иммунной системой, как чужеродные антигены. Также IgG4 реализуют эффекторные механизмы: связывание со специализированными иммунными клетками, осуществляющими после такого взаимодействия фагоцитоз чужеродных агентов или уничтожение зараженных клеток организма за счет зависимой от антител цитотоксичности. Мнения относительно способности IgG4 активировать комплемент зачастую противоречивы. Повышение концентрации иммуноглобулинов данного подкласса может свидетельствовать не только о развитии инфекционных и аллергических состояний, но и о наличии у пациента IgG4-сопряженной патологии. IgG4-сопряженная патология (IgG4-СП) — относительно недавно выделенная группа патологических состояний, и ее изучение становится все более актуальным. Это связано с тем, что она включает в себя состояния, которые ранее считались самостоятельными нозологическими единицами. В последние годы IgG4-СП диагностируется все чаще, так как получает все большее признание у медицинской общественности. Данный обзор включает новейшую информацию из последних зарубежных публикаций.
- Open Access
- 27 October 2016
- Published by Synapse, LLC in The Russian Archives of Internal Medicine
- Vol. 6 (5) , 5-11
THE MAIN MARKERS OF AUTOIMMUNE RHEUMATIC DISEASES AND THEIR INTERPRETATION
Целью этой работы является систематизация данных о маркерах аутоиммунных ревматических болезней. В статью включена базовая информация с учетом последних рекомендаций от 2014 года. Весь материал представлен в виде таблиц, для удобного использования в повседневной практике любого специалиста.
- 27 October 2016
- Published by Synapse, LLC in The Russian Archives of Internal Medicine
- Vol. 6 (5) , 5-11
Open AccessTHE MAIN MARKERS OF AUTOIMMUNE RHEUMATIC DISEASES AND THEIR INTERPRETATION
Целью этой работы является систематизация данных о маркерах аутоиммунных ревматических болезней. В статью включена базовая информация с учетом последних рекомендаций от 2014 года. Весь материал представлен в виде таблиц, для удобного использования в повседневной практике любого специалиста.
- Open Access
- 1 January 2016
- Published by Synapse, LLC in The Russian Archives of Internal Medicine
- Vol. 6 (6) , 72-78
CAMERON LESIONS: LITERATURE REVIEW AND CASE PRESENTATION
СИНДРОМ КЭМЕРОНА: ОБЗОР ЛИТЕРАТУРЫ И ОПИСАНИЕ КЛИНИЧЕСКОГО СЛУЧАЯ
- 1 January 2016
- Published by Synapse, LLC in The Russian Archives of Internal Medicine
- Vol. 6 (6) , 72-78
Open AccessCAMERON LESIONS: LITERATURE REVIEW AND CASE PRESENTATION
СИНДРОМ КЭМЕРОНА: ОБЗОР ЛИТЕРАТУРЫ И ОПИСАНИЕ КЛИНИЧЕСКОГО СЛУЧАЯ
- 1 January 2009
- Vol. 87 (10) , 59-60
[Neurologic manifestations of HIV infection].
The sole universally recognized diagnostic criterion for the affection of central nervous system by immunodeficiency virus is AIDS-dementia complex. Its main pathognomonic feature is progressive intellect failure although most patients do not experience intellect deficit. Instead, they present with other disorders in the central nervous system. This article focuses on their early diagnosis.
- 1 January 2009
- Vol. 87 (10) , 59-60
[Neurologic manifestations of HIV infection].
The sole universally recognized diagnostic criterion for the affection of central nervous system by immunodeficiency virus is AIDS-dementia complex. Its main pathognomonic feature is progressive intellect failure although most patients do not experience intellect deficit. Instead, they present with other disorders in the central nervous system. This article focuses on their early diagnosis.